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• Although mast cells have been implicated in many vas- 
cular and inflammatory reactions, the mechanisms underly- 
ing such mast cell-dependent processes have not been fully 
clarified. Recently we have established an association between 
mast cells and local thrombus formation. The most useful 
model for studying molecular mechanisms of mast cell- 
thrombosis interactions appeared to be auricular thrombosis. 
In the present review we summarize our findings in patients 
with auricular thrombosis with regard to functionally impor- 
tant molecules that can either be expressed and released by 
cardiac mast cells or interact with mast cells via distinct cell 
surface molecules. The potential prothrombolytic function of 
mast cells in atrial thrombosis is discussed. 
INTRODUCTION 
• Mast cells (MC) are multifunctional immune cells in 
loose connective tissue. These cells are usually located in vi- 
cinity to small blood vessels (1-3). Human MC produce a num- 
ber of vasoactive or thromboactive mediators including hista- 
mine, heparin, proteolytic enzymes or cytokines (4-7). Some 
of these compounds, such as heparin, tryptase and chymase, 
are almost exclusively expressed in MC. Human MC have been 
implicated in vascular and inflammatory reactions. However, 
the molecular mechanisms which are involved in MC depen- 
dent processes are not well understood. 
It has been shown that differentiation of human MC from their 
progenitor cells in vitro is inducible by distinct stromal cells 
such as 3T3 fibroblasts (8). One factor involved has been iden- 
tified and termed mast cell growth factor (MGF). This cytokine 
is also well-known as stem cell factor, steel factor or c-kit 
ligand (9-12). The receptor for MGF belongs to the tyrosine 
kinase family, subtype III, and is encoded by the c-kit proto- 
oncogene (13). Recently, this receptor has been clustered as 
CD 117 (14). Two molecular forms of human MGF have been 
described: a membrane bound form and a soluble one. These 
two forms are generated by tissue-specific splicing (11,12,15). 
Mice with mutations at the c-kit locus or at the MGF one typi- 
cally exhibit anemia, absence of MC, white spotting of the 
skin, and sterility (1). Thus, MGF-c-kit receptor interactions 
are critical for normal hematopoiesis and development and 
survival of MC, cutaneous melanocytes and germ cells (13). 
Recent studies have demonstrated that multiple functions in- 
cluding growth, mediator production and secretion as well as 
chemotaxis (16,17) of MC are regulated by MGF (18,19). 
MGF is expressed by stromal cells, including fibroblasts and 
vascular endothelial cells (13,20). In vitro studies have shown 
that thrombin, interleukin-1, and tumor necrosis factor (TNF- 
a) can induce expression of MGF in endothelial cells (20). 
The soluble form of MGF is made abundantly and is present 
in human peripheral blood at a concentration of approximately 
1-10 ng/ml (21) which is in the range that can promote me- 
diator release from isolated human skin MC in vitro (22). How- 
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ever, very little is known about the tissue levels of membrane 
bound or soluble forms of MGF produced in vivo. 
The c-kit receptor is expressed in immature bone marrow cells, 
oocytes, neural cells, and melanocytes. In addition, both im- 
mature MC progenitors and mature tissue MC express MGF 
binding sites. 
CARDIAC MAST CELLS 
• Recently, the human cardiac MC have been character- 
ized by our group (23). Phenotypical, functional and biochemi- 
cal characteristics are closely related to MC of other body re- 
gions. Elevated number of MC were found in the atrial append- 
ages of human hearts compared to the ventricular wall. The 
reason for this physiologic augmentation is unknown. We also 
investigated atrial appendages for changes in MC number, dis- 
tribution and phenotype in disease states of the appendage, 
namely auricular thrombosis, in order to elucidate a possible 
role of MC and their mediators in thrombogenesis (24). 
AURICULAR THROMBOSIS 
• The predilection site for thrombus formation in the 
human heart apart from cardiac infarction areas is the atrial 
appendage (25). The reason for the predilection of the auricle 
may be its distinct anatomy as well as the abnormalities in blood 
flow patterns. Patients with atrial fibrillation reveal a signifi- 
cantly reduced or absent blood flow with stasis (26-28). Other 
studies have shown that atrial appendage thrombus formatioi 
went along with auricular dilatation as well as decreased con 
traction (27,29). The increased incidence of thrombus forma 
tion in atrial fibrillation implies a role for hemodynamic fac 
tors. It has been demonstrated that atrial thrombus formatioi 
is associated with decreased atrial appendage contraction and 
atrial appendage dilatation (29). Anticoagulant therapy in atrial 
fibrillation lowers the risk of stroke indicating the involvemen 
of humoral factors in thrombogenesis (30,31). Furthermore 
during anticoagulant therapy the thrombotic atrial mass maj 
even decrease in size or dissolve (32-34). These observation 
point to endogenous prothrombolytic mechanisms, since con 
ventional anticoagulation exhibits no throm-bolytic effect b 
itself. Endothelial and subendothelial cells may also contrib 
ute to local thrombus formation and/or thrombolysis due to thei 
active role in the regulation of blood coagulation (35,36). S 
far, the exact molecular mechanisms and cell types involve 
in thrombosis and thrombolysis could not be defined. 
MAST CELLS AND MGF IN AURICULAR 
THROMBOSIS 
• In recent studies (23,24), we could demonstrate a sig 
nificant augmentation of atrial MC in patients with auricula 
thrombosis (Fig. 1) and a redistribution of augmented MC to 
the upper endocardium, close to the thrombus (Fig.2). Thes 
changes in the endocardium of thrombosed auricles were ac- 
companied with an overexpression of the c-kit ligand MGF 
and downregulation of c-kit receptor on the redistributed MC. 
In addition, none of those phenomena were observed in fibril- 
  
 
Figure 1. Number of mast cells (MC) per mm
2
 in thrombosed (black) and non-thrombotic contralateral auricles (grey) of 
patients suffering from auricular thrombosis and 'normal' control auricles (white). MC increase significantly in the myo- 
cardium and the endocardium of thrombosed atrial appendages but do not in the non-thrombotic auricles of the same 
patients. Moreover, MC redistribute to the upper endocardium in thrombosed auricles. 
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Figure 2. Three redistributed mast cells (MC) (arrows) in the upper endocardium in a patient with auricular thrombosis. 
MC were visualized by immunoperoxidase staining technique using mAbs to MC tryptase. 
  
lating non-thrombotic contralateral appendages of the same 
patients or unaffected auricles of control patients suffering from 
atrial fibrillation (Fig. 1). Moreover, no significant correlation 
between MC number and atrial fibrillation onset could be 
found. Taken together these data, atrial fibrillation is not likely 
to trigger MC augmentation. The changes in thrombosed ap- 
pendages were not due to an unspecific inflammatory process 
because neither macrophages, lymphocytes, nor polymorpho- 
nuclear leukocytes were significantly increased, neither in the 
endocardium, nor in the myocardium. This observation was 
farther supported by the fact that no upregulation of the leu- 
kocyte adhesion molecules ICAM-1, VCAM-1, ELAM-1, and 
PEC AM-1 could be substantiated in auricular thrombosis. 
A possible link between MC and thrombosis has already been 
considered. In 1955, Sundberg reported on an increase of 
perivascular MC above average in certain thrombotic diseases 
(37). Three years later, Pomerance (38) observed an increase 
of MC in the adventitia of thrombosed coronary arteries. Stud- 
ies by Kitamura et al (39) and Hatanaka et al (40) have shown 
that MC-deficient mice are hyperresponsive to thrombogenic 
stimuli. An augmentation of MC was also seen in coronary 
thrombosis in cocaine abusers and in early lesions of athero- 
sclerosis (41,42). 
The observed MC redistribution in auricular thrombosis is 
associated with an overexpression of MGF in the upper en- 
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docardium (24). This cytokine promotes the development of 
human MC from their progenitors present in bone marrow 
(43) and in peripheral blood (19). Additionally, MGF is a 
chemotactic factor increasing the directional motility of MC 
(16,17). Both effects of MGF could contribute to the MC aug- 
mentation in auricular thrombosis. MC accumulation in the 
endocardium of thrombosed auricles could be due to local dif- 
ferentiation from progenitor cells or due to chemoattractance 
of mature MC. The hypothesis of MGF as a key regulator of 
MC distribution is supported by several observations. Abnor- 
mal production of MGF was found in cutaneous lesions of 
patients with mastocytosis (44). Galli et al (45) administered 
human recombinant MGF to monkeys and observed an ex- 
pansion of the MC population in many tissues and organs. It 
is reasonable to assume that locally overexpressed MGF plays 
an important role in the accumulation of MC either by local 
differentiation or by chemoattractance. 
Redistributed MC in the upper endocardium of thrombosed 
auricles, where MGF, their natural ligand, is overexpressed, 
displayed weaker or absent reactivity with mAbs to c-kit when 
compared either to MC in the lower endocardium and myo- 
cardium of thrombosed appendages, or to MC in control au- 
ricles (24). One explanation for this phenomenon could be 
that receptors were covered by locally expressed MGF. On the 
other hand, MGF is known to cause downregulation of c-kit 
mRNA in MC, so that the loss of c-kit receptors from the cell 
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surface may be explained by ligand induced downregulation 
of c-kit protein production (46-48). 
Our findings of MGF overexpression and c-kit downregulation 
in auricular thrombosis might have functional implications. 
MC can release their mediators as a consequence of MGF 
stimulation. This has already been demonstrated for lung MC 
(18) and confirmed for cardiac MC (24). There is accumulat- 
ing evidence that the c-kit signal transduction pathway can 
also be activated through intimate cell-to-cell contact between 
proliferating cells expressing the c-kit receptor and tissue-an- 
chored stromal cells expressing the membrane-bound ligand 
(11,49). Thus, it is tempting to speculate that the overexpressed 
c-kit ligand in the upper endocardium may cause or promote 
mediator release in locally augmented MC. Since MC are a 
unique source of heparin (1,50,51), preventing further appo- 
sition of thrombotic material, and a source of proteolytic en- 
zymes, including prothrombolytic tissue plasminogen activa- 
tor (52), one may speculate that locally accumulated MC can 
participate in endogenous thrombolysis. 
COHCLUSIOMS 
• The association between atrial appendage thrombosis, 
MC augmentation, MC redistribution and MGF overexpression 
may lead to the hypothesis that augmented and redistributed 
MC and their mediators play an important role in the patho- 
physiology of atrial thrombosis. 
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